PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07047807
Status
Recruiting
Apply to this trial

Conditions

  • PDAC - Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PDAC-PATHWAYS — BEHAVIORAL
    A digital app for patients initiating neoadjuvant therapy for PDAC
  • Usual Care — OTHER
    Routine treatment

Study Details

This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).

Key Dates

Start date
Oct 6, 2025
Status verified
Apr 2026
Primary completion
May 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: PDAC-PATHWAYS
    PDAC-PATHWAYS is an informational and supportive care app for patients initiating neoadjuvant therapy for PDAC.
  • Active Comparator: Usual care
    Participants randomized to usual care will receive routine treatment with their oncology clinicians.

Primary Outcome Measure

Feasibility: Enrollment rate [ Time Frame: 10 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Kelsey Lau-Min, MD, MSCE
[email protected]
857-367-1486
Kelsey Lau-Min, MD, MSCE (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies